Human Health Portfolio NorthSea Therapeutics Bolsters Board, as Orziloben Moves into Late-stage Development March 31, 2026 PDF 270.6 KB Download
Human Health Portfolio NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) February 21, 2024 PDF 186.0 KB Download
Human Health Portfolio NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease October 17, 2023 PDF 199.1 KB Download
Human Health Portfolio NorthSea Therapeutics appoints Morris J. Birnbaum to the Board December 21, 2022